BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
NASA's make-or-break moon shot - 2Kids may be more likely to get the new ‘Cicada’ variant of Covid-19, scientists say. Here’s what to know about BA.3.2
- 3New York to require social media platforms to display mental health warnings
- 4The Ascent of Rousing Pioneers Who Formed History
- 5Audits of 6 European Busssiness Class Flights
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Merz postpones Norway trip for Belgium talks on frozen Russian assets
- Antivirus Programming for Exhaustive Security
- Historical mysteries solved by science in 2025
- Clocks to go forward one hour in Europe as summer time starts
- Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- How effective is the flu shot this year? New report shows promising results
- New science points to 4 distinct types of autism
- IDF destroys regime's missile, sea mine production site in Yazd amid nationwide airstrikes
